CorMedix (CRMD) Net Income towards Common Stockholders: 2012-2025
Historic Net Income towards Common Stockholders for CorMedix (CRMD) over the last 12 years, with Sep 2025 value amounting to $108.5 million.
- CorMedix's Net Income towards Common Stockholders rose 4001.20% to $108.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $163.0 million, marking a year-over-year increase of 496.10%. This contributed to the annual value of -$17.9 million for FY2024, which is 62.52% up from last year.
- CorMedix's Net Income towards Common Stockholders amounted to $108.5 million in Q3 2025, which was up 434.36% from $20.3 million recorded in Q2 2025.
- CorMedix's 5-year Net Income towards Common Stockholders high stood at $108.5 million for Q3 2025, and its period low was -$14.5 million during Q1 2024.
- Its 3-year average for Net Income towards Common Stockholders is $10.0 million, with a median of -$6.3 million in 2023.
- As far as peak fluctuations go, CorMedix's Net Income towards Common Stockholders slumped by 250.96% in 2023, and later soared by 4,001.20% in 2025.
- Quarterly analysis of 5 years shows CorMedix's Net Income towards Common Stockholders stood at -$7.8 million in 2021, then fell by 5.36% to -$8.2 million in 2022, then crashed by 42.18% to -$9.7 million in 2023, then soared by 71.45% to $13.5 million in 2024, then skyrocketed by 4,001.20% to $108.5 million in 2025.
- Its Net Income towards Common Stockholders was $108.5 million in Q3 2025, compared to $20.3 million in Q2 2025 and $20.6 million in Q1 2025.